Neovasc Inc. Reports Year 2008 Financial Results



    
    --Major Actions Implemented During 2008 Position the Company for Future
    Growth--

    TSX Venture Exchange: NVC
    

    VANCOUVER, April 24 /CNW/ - Neovasc Inc. (TSXV: NVC), today announced
financial results for the year ended December 31, 2008.
    "The fundamental changes Neovasc implemented during the past year have
involved hard choices, but we believe they have resulted in a lean and highly
focused company that is well-positioned for the future," said Neovasc chief
executive officer Alexei Marko. "We have wrung major costs out of every part
of the firm, from closing facilities and reducing headcount to shelving those
products and distribution channels with little chance of contributing
meaningfully to near-term growth. Going forward, we are concentrating on those
business segments with the greatest growth potential over the next 18 months
and where we believe we can be successful without incurring significant costs.
These include our tissue business, which in 2009 should benefit from our
recent distribution agreement with vascular leader LeMaitre Vascular, as well
as from other agreements with strategic partners that are in place or under
discussion."
    Mr. Marko continued, "We remain very optimistic about the clinical and
commercial potential of our Reducer(TM) stent, a development stage product
with the potential to revolutionize the treatment of refractory angina, which
currently affects over two million patients, and we look forward to filing a
CE Mark application for this important product during 2009. We continue to be
proactive in seeking near-term revenue opportunities that are synergistic with
our current business and that provide strong returns on investment. We believe
our current businesses and our revamped strategy play to Neovasc's strengths,
and we look forward to reporting on our progress over the course of the year."
    Neovasc chief financial officer Chris Clark noted, "Actions we took in
2008 to rationalize our staffing and cost structure and re-organize our
balance sheet resulted in a number of sobering financial figures at year end.
We believe that recognizing these required non-cash impairment charges now
should be advantageous to our financial results in the future. On April 23,
2009, we also completed a non-brokered private placement that resulted in
gross proceeds to Neovasc of $2 million, reinforcing the company's cash
position as we advance our most promising products and technologies."

    Financial Results

    Results for the year ended December 31, 2008 follow. All amounts are in
Canadian dollars.

    Net Losses
    The consolidated net loss for the year ended December 31, 2008 was
$34,259,565 or $2.94 basic loss per share as compared with a net loss of
$7,830,954 or $1.59 basic loss per share for the comparative period in 2007.
The increase in loss of approximately $26 million is substantially due to a
non-cash $23 million impairment charge on technology and goodwill, a non-cash
$2 million increase in amortization expense on technology and a $1 million
increase in other losses.

    Impairment of Goodwill and Technology
    During the fourth quarter of 2008, the Company's market capitalization
remained below the value of the shareholders equity for a significant period
of time, indicating potential impairment of the Company's goodwill and other
intangible assets. As a result of these market indicators and the Company's
impairment testing, the Company recorded an impairment charge of $3,557,082 to
write down acquired goodwill to $nil and an impairment charge of $19,503,930
to write down the net book value of acquired technologies to $nil.

    Termination of Distribution Agreement
    On December 22, 2008, the distribution agreement between Neovasc and a
third party distributor was terminated. On termination the Company was
required to repurchase inventory held by the distributor less a 25% restocking
fee. Under EIC-156 Accounting by a vendor for consideration given to a
Customer, Neovasc is required to recognize the inventory repurchase as a
reduction in revenue and the income statement impact of the termination was to
reduce revenue by $516,601, decrease cost of goods sold by $308,203 and
recognize interest income of $45,024 (for the interest due on accounts
receivable from the distributor).

    Inventory Write Down
    During the last quarter of the year, Neovasc severed its direct sales
force employees who sold the Company's Metricath products and terminated its
distributor of Aegis products. As a result, the Company has limited sales
channels through which to sell the Metricath and Aegis product lines. While
management continues to look for new distributors to carry these products,
there is no certainty, when, or if, they will be able to find a suitable
partner. With no certain sales in 2009 from these products the Company
incurred an inventory write down of $626,925.

    Repayable Contribution Write Back
    As noted above, the Metricath products do not currently have an
established sales channel and Neovasc cannot predict whether or not it will be
able to establish a suitable channel in the future or generate revenue from
these products in 2009. As a result, the Company released $320,445 liability
for the repayable contribution agreement repayable from royalties generated
from future Metricath sales.

    Revenues
    Revenues increased 2% year over year from $1,517,873 for the year ended
December 31, 2007 to $1,546,239 for the year ended December 31, 2008. Sales of
catheter products for the year ended December 31, 2008 were $262,118 a
marginal increase over sales of $258,017 in the comparable period in 2007,
despite a heavy investment in a direct sales force and a substantial marketing
effort. As described above, the direct sales force has been terminated and the
Company is looking for a new distributor to carry its Metricath product. Sales
of tissue and surgical products and services for the year ended December 31,
2008 were $1,284,121, as compared to sales of $1,259,856 for the year ended
December 31, 2007, a marginal increase of approximately 2%. These revenues
were derived from the sales of Peripatch products and contract manufacturing
revenues. In the fourth quarter the Company reduced revenues by $516,601
associated with the repurchase of inventory from a terminated distribution
agreement. Revenue in the prior quarters was correctly recognized at that time
and the reduction in revenue arises solely from the termination of the
distribution agreement in accordance with EIC 156 - Accounting by a vendor for
consideration given to a Customer.

    Cost of Sales
    The cost of sales for the year ended December 31, 2008 were $708,300 as
compared to $799,593 in 2007, and the overall gross margin for 2008 was 54% as
compared to 47% in 2007. The gross margin for 2008 has been positively
impacted by termination of the distribution agreement discussed above. Due to
the 25% restocking fee, only 75% of the inventory returned resulted in a
payment obligation of the Company and a corresponding revenue reduction, while
100% of the reacquired inventory was recognized and resulted in a reversal of
cost of goods sold. The 25% of revenue remaining effectively has a zero cost
of goods and positively impacts the gross margin for 2008.

    Expenses
    Total expenses for the year ended December 31, 2008 and 2007 were
$35,498,908 and $8,631,675 respectively. The increase in expenses from 2007 to
2008 can be explained by an increase in operating expenses associated with
additional costs incurred by the newly acquired activities in Israel of
$1,940,462, an increase in amortization on intangible assets of $2,129,570, an
impairment of intangible assets of $23,061,012, inventory write down of
626,925, and an offsetting recovery on the repayable contribution agreement of
$320,445.

    Liquidity and Capital Resources
    The Company finances its operations and capital expenditures with cash
generated from operations, lines of credit, long-term debt and equity
financings. At December 31, 2008, the Company had cash and cash equivalents of
$2,498,439 as compared to cash of $3,242,404 as of December 31, 2007. At
December 31, 2008 the Company had working capital of $2,123,519 as compared to
working capital of $3,431,266 at December 31, 2007. In addition, at December
31, 2008 the Company had restricted cash related to a security on long-term
debt of $50,000 (December 31, 2007 - $50,000) included in long-term assets.
Cash used in operations was $8,477,808 for the year ended December 31, 2008,
as compared to $6,439,828 for the year ended December 31, 2007, an increase of
$2,037,980. The increase in cash usage was related to the increase in expenses
borne by the Company at the newly acquired operations in Israel and in
increased sales and marketing expenditures.



    
    Neovasc Inc. (formerly Medical Ventures Corp.)
    Consolidated Balance Sheets
    As at December 31
    -------------------------------------------------------------------------

                                                          2008          2007
    -------------------------------------------------------------------------

    ASSETS

    CURRENT
      Cash and cash equivalents                   $  2,498,439  $  3,242,404
      Accounts receivable                              470,200       568,964
      Inventory                                        341,564       384,124
      Prepaid expenses and other assets                 52,356        18,755
    -------------------------------------------------------------------------
                                                     3,362,559     4,214,247
    RESTRICTED CASH AND CASH EQUIVALENTS                50,000        50,000
    RETIREMENT ASSETS                                    8,320             -
    TECHNOLOGY                                               -             -
    GOODWILL                                                 -             -
    PROPERTY AND EQUIPMENT                           1,399,644     1,425,553
    -------------------------------------------------------------------------
                                                  $  4,820,523  $  5,689,800
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    LIABILITIES

    CURRENT
      Accounts payable and accrued liabilities    $  1,218,405  $    735,310
      Current portion of long-term debt                 20,635        19,559
      Current portion of repayable
       contribution agreement                                -        28,112
    -------------------------------------------------------------------------
                                                     1,239,040       782,981
    LONG-TERM DEBT                                     418,612       441,540
    REPAYABLE CONTRIBUTION AGREEMENT                         -       283,959
    RETIREMENT LIABILITIES                               8,964             -
    -------------------------------------------------------------------------
                                                     1,666,616     1,508,480
    -------------------------------------------------------------------------

    SHAREHOLDERS' EQUITY

    Share capital                                   58,607,066    28,835,081
    Contributed surplus                              4,436,804       976,637
    Deficit                                        (59,889,963)  (25,630,398)
    -------------------------------------------------------------------------
                                                     3,153,907     4,181,320
    -------------------------------------------------------------------------
                                                  $  4,820,523  $  5,689,800
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



    Neovasc Inc. (formerly Medical Ventures Corp.)
    Consolidated Statements of Operations, Comprehensive Loss and Deficit
    For the year ended December 31
    -------------------------------------------------------------------------

                                                          2008          2007
    -------------------------------------------------------------------------

    SALES
      Product sales                               $  1,452,854  $  1,209,832
      Consulting services                               93,385       308,041
    -------------------------------------------------------------------------
                                                     1,546,239     1,517,873
    COST OF SALES,
      including underutilized capacity of $32,166
       (2007: $155,888)                                708,300       799,593
    -------------------------------------------------------------------------
    GROSS PROFIT                                       837,939       718,280
    -------------------------------------------------------------------------

    EXPENSES
      Selling                                        3,245,886     2,839,897
      General and administration                     3,459,800     2,282,283
      Product development and clinical trials        3,101,869     2,744,913
      Impairment of intangible assets               23,061,012             -
      Inventory write down                             626,925       559,131
      Recovery on repayable contribution agreement    (320,445)            -
      Amortization on intangible assets              2,129,570             -
      Amortization                                     194,291       205,451
    -------------------------------------------------------------------------
                                                    35,498,908     8,631,675
    -------------------------------------------------------------------------
    LOSS BEFORE OTHER INCOME (EXPENSES)            (34,660,969)   (7,913,395)
    -------------------------------------------------------------------------
    OTHER INCOME (EXPENSES)
      Interest income                                  153,277       165,562
      Interest on long-term debt                       (27,288)      (14,136)
      Accreted interest on repayable
       contribution agreement                          (15,479)      (14,891)
      Gain (Loss) on foreign exchange                  290,894       (54,094)
    -------------------------------------------------------------------------
                                                       401,404        82,441
    -------------------------------------------------------------------------
    NET LOSS AND COMPREHENSIVE
     LOSS FOR THE PERIOD                           (34,259,565)   (7,830,954)
    DEFICIT, BEGINNING OF PERIOD                   (25,630,398)  (17,900,437)
    ADJUSTMENT FOR CHANGE IN ACCOUNTING POLICY               -       100,993
    -------------------------------------------------------------------------
    DEFICIT, END OF PERIOD                        $(59,889,963) $(25,630,398)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    -------------------------------------------------------------------------
    BASIC AND DILUTED LOSS PER SHARE              $      (2.94) $      (1.59)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    -------------------------------------------------------------------------
    WEIGHTED AVERAGE NUMBER OF
     COMMON SHARES OUTSTANDING                      11,630,939     4,936,248
    WEIGHTED AVERAGE NUMBER OF
     FULLY DILUTED SHARES OUTSTANDING               12,172,746     4,936,248
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



    Neovasc Inc. (formerly Medical Ventures Corp.)
    Consolidated Statements of Cash Flows
    For the year ended December 31
    -------------------------------------------------------------------------
                                                          2008          2007
    -------------------------------------------------------------------------
    OPERATING ACTIVITIES
      Net loss for the period                     $(34,259,565) $ (7,830,954)
      Items not affecting cash
        Intangible assets impairment                23,061,012             -
        Inventory write down                           626,925       559,131
        Recovery of repayable
         contribution agreement                       (320,445)            -
        Amortization                                 2,323,861       205,451
        Interest on repayable
         contribution agreement                         15,479        14,891
        Stock-based compensation                       387,360       166,885
    -------------------------------------------------------------------------
                                                    (8,165,373)   (6,884,596)

      Change in non-cash operating
       assets and liabilities
        Accounts receivable                            508,038      (367,882)
        Inventory                                     (584,365)      216,609
        Prepaid expenses and other assets              (24,376)       69,433
        Retirement assets                               72,295             -
        Accounts payable and accrued liabilities      (184,183)      526,608
        Retirement liabilities                         (99,844)            -
    -------------------------------------------------------------------------
                                                    (8,477,808)   (6,439,828)
    -------------------------------------------------------------------------
    INVESTING ACTIVITY
      Acquisition of business,
       net of cash of $781,008
        B-Balloon Ltd.                                (274,858)            -
        Neovasc Medical Ltd.                           210,625             -
      Purchase of property and equipment               (47,765)     (542,316)
    -------------------------------------------------------------------------
                                                      (111,998)     (542,316)
    -------------------------------------------------------------------------
    FINANCING ACTIVITIES
      Increase in long-term debt                             -       298,911
      Repayment of long-term debt                      (21,852)      (19,101)
      Repayment of loan from related
       party of B-Balloon                             (356,440)            -
      Repayment of repayable
       contribution agreement                           (7,105)       (5,418)
      Proceeds from share issue, net of costs        8,231,088     7,091,111
      Proceeds on exercise of agents warrants                -       232,310
      Proceeds from exercise of stock options              150             -
    -------------------------------------------------------------------------
                                                     7,845,841     7,525,813
    -------------------------------------------------------------------------
    (DECREASE)/INCREASE IN CASH                       (743,965)      543,669
    CASH AND CASH EQUIVALENTS,
      BEGINNING OF PERIOD                            3,242,404     2,698,735
    -------------------------------------------------------------------------
      END OF PERIOD                               $  2,498,439  $  3,242,404
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    REPRESENTED BY:
      Cash                                             181,228        93,649
      Cashable guaranteed investment certificates    2,317,211     3,148,755
    -------------------------------------------------------------------------
                                                  $  2,498,439  $  3,242,404
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    NON CASH TRANSACTIONS
      Change in Asset Use                                    -       131,794
      Issuance of shares to acquire
        B-Balloon and Neovasc Medical               24,613,554             -
      Issue of Warrants                                      -       111,518
    SUPPLEMENTAL CASH FLOW INFORMATION
      Interest paid                                     27,288        14,136
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    

    About Neovasc Inc.

    Neovasc Inc. is a new specialty vascular device company that develops,
manufactures and markets medical devices for the rapidly growing vascular and
surgical marketplace. The company's current products include the Neovasc
ReducerTM, a novel stent in development to treat refractory angina, as well as
a line of advanced biological tissue technologies that are used to enhance
surgical outcomes and as key components in a variety of third party medical
products. For more information, visit: www.neovasc.com.

    Statements contained herein that are not based on historical or current
fact, including without limitation statements containing the words
"anticipates," "believes," "may," "continues," "estimates," "expects," and
"will" and words of similar import, constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include, among others, the following: general economic and business
conditions, both nationally and in the regions in which the Company operates;
history of losses and lack of and uncertainty of revenues, ability to obtain
required financing, receipt of regulatory approval of product candidates,
ability to properly integrate newly acquired businesses, technology changes;
competition; changes in business strategy or development plans; the ability to
attract and retain qualified personnel; existing governmental regulations and
changes in, or the failure to comply with, governmental regulations; liability
and other claims asserted against the Company; and other factors referenced in
the Company's filings with Canadian securities regulators. Although the
Company believes that expectations conveyed by the forward-looking statements
are reasonable based on the information available to it on the date such
statements were made, no assurances can be given as to the future results,
approvals or achievements. Given these uncertainties, readers are cautioned
not to place undue reliance on such forward-looking statements. The Company
does not assume the obligation to update any forward-looking statements except
as otherwise required by applicable law.





For further information:

For further information: Corporate contact: Neovasc Inc., Chris Clark,
(604) 248-4138; U.S. media & investor contact: GendeLLindheim BioCom Partners,
Barbara Lindheim, (212) 918-4650


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890